Background
==========

Cancer is a major public health problem and results in significant morbidity and mortality worldwide \[[@b1-medscimonit-25-8315]\]. Many studies show that the process of carcinogenesis is always companied with inflammation. Therefore, certain inflammatory cytokines promote or inhibit tumor development \[[@b2-medscimonit-25-8315]\].

As prominent factors during the process, interferons exert their various roles by inducing the expression of many proteins \[[@b3-medscimonit-25-8315]\]. For instance, endoribonuclease L (RNASEL), induced by interferons, is associated with the antiproliferative and antiviral effects of interferon \[[@b4-medscimonit-25-8315]\]. *RNASEL* gene expression and mutation have been receiving increased research attention.

Single-nucleotide polymorphisms (SNPs) of some genes affect the function of these genes. Sequence analysis of *RNASEL* gene has identified the 2 most common corresponding SNPs: rs486907 G\>A and rs627928 T\>G \[[@b5-medscimonit-25-8315],[@b6-medscimonit-25-8315]\]. These SNPs has been reported to affect the expression and activity of the protein derived from the *RNASEL* gene \[[@b7-medscimonit-25-8315],[@b8-medscimonit-25-8315]\]. RNASEL has been demonstrated to play a role in carcinogenesis, such as in prostate cancer \[[@b9-medscimonit-25-8315],[@b10-medscimonit-25-8315]\]. Thus, rs486907 and rs627928 are thought to be involved in prostate cancer susceptibility.

Recent studies have shown the association between risk of prostate cancer and these SNPs of RNASEL. Unfortunately, the conclusions in these studies were not consistent. To resolve these inconsistent results, several meta-analyses on rs486907 and rs627928 were conducted up to 2011. For the next 6 years, 14 original studies on this scientific problem were also carried out. However, the conclusions in these studies remain controversial. Therefore, we performed this updated meta-analysis, including new studies, and attempted to assess the role of these SNPs in tumor development \[[@b4-medscimonit-25-8315]--[@b6-medscimonit-25-8315],[@b11-medscimonit-25-8315]--[@b36-medscimonit-25-8315]\].

Material and Methods
====================

Search strategy
---------------

All relevant articles were collected from PubMed, Web of Science, Scopus, CNKI, and WanFang databases before August 2018. The search keywords were: "SNP" and "RNASEL or Ribonuclease L" and "cancer or tumor or neoplasm or carcinoma" and "polymorphism". Additional relevant studies were found by manually screening the references in reviews and the identified articles. The quality of the studies included in our meta-analysis were evaluated using the Newcastle-Ottawa scale.

Inclusion and exclusion conditions
----------------------------------

Study inclusion criteria were: (a) evaluation of the relationship between rs486907 and rs627928 and the risk of prostate cancer; (b) case-control design; (c) published in Chinese or English; and (d) enough data obtained in the studies, including the amounts of these genotypes (for rs486907 and rs627928) in cases and controls, which could be used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs).

Exclusion criteria were: (a) abstracts from conferences and reviews; (b) case only studies; (c) duplicate studies; and (d) studies without detailed genotyping information.

Data extraction
---------------

The data in eligible studies were extracted by 2 investigators. The following elements from each study were collected: the (first) author name, edition year, district, people and populations, the quality of each study, control source, tumor types, the numbers of controls and cases, the genotype distribution for rs486907 and rs627928, the minor allele frequency (MAF) in each study, and the result of Hardy-Weinberg equilibrium (HWE) test.

Statistical analysis
--------------------

The chi-square test was used to assess deviation from HWE in controls. The evaluation of the relationship between these SNPs of *RNASEL* gene and prostate cancer susceptibility was performed using ORs and 95% CIs. Pooled ORs were assessed using the Z test in the following 5 genetic models: allele, recessive, dominant, homozygous, and heterozygous models.

The heterogeneity among the studies included for meta-analysis were checked by Q-test based on chi-square test by using the I^2^ index value. If *P*\<0.10 and I^2^ \>50%, the significant heterogeneity could not be ignored. Hence, the pooled OR was obtained through the random-effects model. If not, the fixed-effects model was used. Stratification was conducted based on ethnicity and cancer type.

The impact of each study on the pooled ORs were checked by sensitivity analysis. Risk of publication bias among studies was evaluated by Begg's test and Egger's test. STATA software (Version 11.0, STATA Corp., College Station, TX, USA) was used for all statistical analyses. All statistics were two-sided and the differences were defined as significant at P \< 0.05.

Ethics review
-------------

Because this meta-analysis was based on previous studies, ethics approval was not required.

Results
=======

Selection of studies and characteristics
----------------------------------------

The flow chart shown in [Figure 1](#f1-medscimonit-25-8315){ref-type="fig"} explains the search process and selection of studies. In total, 417 articles were initially found from PubMed, Web of Science, Scopus, CNKI, and WanFang databases. Of these, 118 were duplicate and were thus excluded; therefore, 299 articles were retrieved. After reading titles and abstracts, 14 review or meta-analysis articles were excluded. After full-text assessment, 247 irrelevant articles were excluded and the remaining 38 articles were then evaluated in detail. Finally, 23 articles including 40 studies were used for this meta-analysis ([Figure 1](#f1-medscimonit-25-8315){ref-type="fig"}). However, the distributions of the control genotypes in 5 studies deviated from HWE, so our final analysis included 22 studies (including 11 135 cases and 10 817 controls) for rs486907 and 13 studies (including 4522 cases and 3823 controls) for rs627928. The characteristics of these studies are summarized in [Table 1](#t1-medscimonit-25-8315){ref-type="table"}. All studies were high quality \[[@b37-medscimonit-25-8315]\], and all focused on prostate cancer. Most of these studies were performed in Caucasian populations.

The results of meta-analysis
----------------------------

rs486907 was not involved in the risk of prostate cancer in 4 genetic models ([Table 2](#t2-medscimonit-25-8315){ref-type="table"}, [Figure 2A](#f2-medscimonit-25-8315){ref-type="fig"}). For rs627928, no obvious heterogeneity was found in allele or recessive models. Hence, the fixed-effects model was used ([Table 2](#t2-medscimonit-25-8315){ref-type="table"}). Our results indicated that rs627928, in allele and recessive models, was related to high risk of prostate cancer ([Table 2](#t2-medscimonit-25-8315){ref-type="table"}, [Figure 2C](#f2-medscimonit-25-8315){ref-type="fig"}).

In subgroup analysis, rs486907 was not involved in prostate cancer susceptibility in Caucasian populations (covering 19 studies) across all genetic models ([Table 2](#t2-medscimonit-25-8315){ref-type="table"}). Furthermore, no obvious association between rs486907 and the risk of onset for prostate cancer was found in African American populations (covering 3 studies) or in non-Hispanic Caucasian populations (covering 3 studies) ([Table 2](#t2-medscimonit-25-8315){ref-type="table"}, [Figure 2B](#f2-medscimonit-25-8315){ref-type="fig"}).

For rs627928, heterogeneity among studies was observed in 5 genetic models in non-Caucasian populations. Consequently, the ORs and 95% CIs were derived from the random-effects model, and the fixed-effects model was used for the other populations ([Table 2](#t2-medscimonit-25-8315){ref-type="table"}).

As expected, our results indicated that rs627928 promotes the development of prostate cancer in African American populations (covering 2 studies) and Caucasian populations (covering 10 studies) in allele, recessive, and homozygous genetic models ([Table 2](#t2-medscimonit-25-8315){ref-type="table"}, [Figure 2D](#f2-medscimonit-25-8315){ref-type="fig"}). However, in non-Caucasian populations, no significant correlation was found between rs627928 and prostate cancer susceptibility ([Table 2](#t2-medscimonit-25-8315){ref-type="table"}).

Sensitivity analysis and publication bias
-----------------------------------------

To assess whether the results of any single study affected the final conclusion in our meta-analysis, we carried out sensitivity analysis to evaluate the influence for both rs486907 and rs627928. We found that our results were not affected by exclusion of individual studies ([Figure 3](#f3-medscimonit-25-8315){ref-type="fig"}).

In addition, the publication bias for both rs486907 and rs627928 was evaluated by Begg's test and Egger's test showing there was no clear evidence of publication bias or trending bias in our analysis ([Table 3](#t3-medscimonit-25-8315){ref-type="table"}).

Trial sequential analysis
-------------------------

To avoid random errors and ensure stability of our results for both rs486907 and rs627928, trial sequential analysis (TSA) was carried out in different genetic models or various populations. However, none of the cumulative Z-curves crossed the trial sequential monitoring boundary or the required information size line ([Figure 4](#f4-medscimonit-25-8315){ref-type="fig"}).

Discussion
==========

Cancers seriously affect patients and impose large economic burdens on society \[[@b1-medscimonit-25-8315]\]. In recent years, more and more research groups have focused on genetic susceptibility to cancer. As a tumor-suppressor gene, *RNASEL* gene polymorphisms (including rs486907 and rs627928) have been demonstrated to be involved in carcinogenesis \[[@b32-medscimonit-25-8315],[@b34-medscimonit-25-8315],[@b38-medscimonit-25-8315],[@b39-medscimonit-25-8315]\].

Many epidemiological studies have recently attempted to identify associations between rs486907 and rs627928 and the risk of prostate cancer. Unfortunately, the conclusions among these studies articles are inconsistent. Six years ago, 5 meta-analyses were carried out to elucidate this relationship \[[@b40-medscimonit-25-8315]--[@b44-medscimonit-25-8315]\]. Li demonstrated that rs627928 leads to high risk of prostate cancer \[[@b40-medscimonit-25-8315]\]. Zhang proved that rs486907 can enhance cancer susceptibility in African American populations, but did not affect the risk of cancer in overall populations \[[@b41-medscimonit-25-8315]\]. Wei found indicated that rs627928 might be a low-risk factor for prostate cancer \[[@b42-medscimonit-25-8315]\]. Mi indicated that rs627928 increases the risk of prostate cancer in African and European populations \[[@b43-medscimonit-25-8315]\]. In an update analysis, Mi et al. \[[@b44-medscimonit-25-8315]\] proved that rs486907 promotes carcinogenesis in prostate cancer in African populations, and rs627928 increases the onset risk of cancer.

During the next few years, several new studies on these SNPs have been published. However, the results of these various studies remain inconsistent 12,13,15\]. Thus, we carried out the present analysis (covering more studies) to clarify the relationship of the 2 SNPs and prostate cancer susceptibility \[[@b4-medscimonit-25-8315],[@b11-medscimonit-25-8315]--[@b15-medscimonit-25-8315]\]. Our results demonstrated that rs627928 is involved in the development of prostate cancer risk, and the conclusion was similar to those of previous meta-analyses. In addition, our analysis proved that rs486907 is not involved in the risk of prostate cancer in overall or in Caucasian populations. Therefore, our conclusion confirms the conclusions of these previous meta-analyses.

*RNASEL* rs486907, also named Arg462Gln, is found in in approximately 13% of prostate cancer patients \[[@b45-medscimonit-25-8315]\]. Winchester et al. found that men with the minor allele of rs486907 appeared to have slightly lower serum prostate-specific antigen (PSA) concentrations than men with the major allele \[[@b46-medscimonit-25-8315]\]. These changes in individuals with rs486907 help explain our results. However, rs627928, also known as Asp541Glu, seems to have nothing to do with this phenomenon \[[@b7-medscimonit-25-8315]\].

For a comprehensive understanding, we have predicted the impact of the 2 RNASEL SNPs at protein level using PolyPhen 2. The data from PolyPhen 2 showed that rs486907 was predicted to possibly damage the function of RNASEL, with a score of 0.864. However, rs627928 was predicted to be benign, with a score of 0.000. The data suggest that rs486907 possibly affects the function of RNASEL protein. Therefore, the SNP could further reduce the incidence of prostate cancer. However, our results indicated that rs627928, but not rs486907, is involved in the risk of prostate cancer.

During the study selection process, the data extracted from 23 articles including 40 studies were used for this meta-analysis. These preselected studies are listed in [Table 1](#t1-medscimonit-25-8315){ref-type="table"}. However, the distributions of the control genotypes in 5 studies deviated from HWE. Therefore, only 22 studies (including 11 135 cases and 10 817 controls) for rs486907 and 13 studies (including 4522 cases and 3823 controls) for rs627928 have been included in our study for the final meta-analysis. In addition to HWE testing, we also assessed the RNASEL 2 polymorphisms MAF reported for the worldwide populations and compared the frequency to the overall estimates reported \[[@b47-medscimonit-25-8315]\]. Data from the PubMed SNP database (*<https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=486907>*) show that the MAFs for rs486907 (the frequency of allele A) were 0.385, 0.291, 0.193, 0.066, and 0.316 in European, Chinese, Japanese, Sub-Saharan African, and Caucasian populations, respectively. In overall populations, the highest MAF was \<0.5. The MAF in each study included in our article was less than 0.5. Hence, no significant difference among them was detected. Data from the PubMed SNP database (*<https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=627928>*) showed that the MAFs for rs627928 (the frequency of allele G) were 0.593, 0.821, 0.634, 0.252, and 0.474 in European, Chinese, Japanese, Sub-Saharan African, and Caucasian populations, respectively. In certain populations, the highest MAF was \<0.5, but the highest MAF was \>0.5 in the other populations. In this meta-analysis, several studies had a MAF \<0.5 and the other studies had a MAF \>0.5, but there was no obvious difference between them.

We found no obvious heterogeneity in the process of analysis, nor did we find any significant publication bias or trending bias. Sensitivity analysis indicated that our conclusion was robust under these conditions, in which individual studies were omitted. However, the TSA data suggested that the false-positive results should not be excluded completely in this study due to its relatively small sample size. Therefore, the results of TSA show that larger studies, specially focusing on Asians and Africans, should be carried out to assess the association between *RNASEL* gene polymorphism and the risk of prostate cancer.

Although all studies enrolled in this analysis met our selection criteria, several limitations of our study should be considered. First, the quantity of studies enrolled in this study was insufficient for subgroup analysis for Asians or Africans. Second, studies on other types of cancer (non-prostate cancer) were not included. Third, a few studies with small samples were enrolled. Last, some important lifestyle data on patients with prostate cancer were not considered.

Although it has some weaknesses, this meta-analysis also makes important contributions. To the best of our knowledge, this is the first meta-analysis to assess the association between these 2 important SNPs and susceptibility to prostate cancer. Our results show that rs627928, but not rs486907, promotes the development of prostate cancer.

Conclusions
===========

Our meta-analysis found no association between rs486907 and risk of prostate cancer, and confirmed that rs627928 promotes the progression of prostate cancer. These results indicate that rs627928 has potential as a predictor of prostate cancer. However, larger studies are needed to validate our conclusions.
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###### 

Characteristics of the studies included in this meta-analysis.

  Author              Year   Region    Ethnicity                Source   Tumor             Case   Control   MAF   HWE    Score                                                
  ------------------- ------ --------- ------------------------ -------- ----------------- ------ --------- ----- ------ ------- ----- ----- ------ ------- ------- --------- ---
  **rs486907 G\>A**                                                                                                                                                           
  Alvarez-Cubero MJ   2015   Spain     Caucasian                HB       Prostate cancer   80     120       37    237    61      114   41    216    0.409   0.454   0.342     7
  Winchester DA       2015   USA       Non-Hispanic Caucasian   PB       Prostate cancer   352    407       105   864    330     372   129   831    0.357   0.379   0.157     7
  San Francisco IF    2014   Chile     Hispanic Caucasian       HB       Prostate cancer   43     31        9     83     11      6     4     21     0.295   0.333   0.102     6
  Arredondo M         2012   Spain     Caucasian                HB       Prostate cancer   17     40        10    67     28      57    20    105    0.448   0.462   0.346     6
  Sakuma T            2011   USA       Caucasian                PB       Prostate cancer   43     55        12    110    11      21    8     40     0.359   0.463   0.723     6
  Meyer MS            2010   USA       Caucasian                PB       Prostate cancer   529    547       159   1235   505     546   159   1210   0.350   0.357   0.551     7
  Agalliu I           2010   USA       Caucasian                PB       Prostate cancer   467    414       84    965    572     556   109   1237   0.302   0.313   0.110     7
  Beuten J            2010   USA       Hispanic Caucasian       PB       Prostate cancer   75     64        17    156    126     91    7     224    0.314   0.234   0.048     6
  Wang MH             2009   USA       Caucasian                PB       Prostate cancer   100    121       27    248    88      132   33    253    0.353   0.391   0.130     6
  Robbins CM          2008   USA       African American         HB       Prostate cancer   183    55        5     243    225     66    5     296    0.134   0.128   0.950     7
  Shea PR             2008   USA       Caucasian                PB       Prostate cancer   187    41        2     230    362     88    2     452    0.098   0.102   0.168     6
  Daugherty SE        2007   USA       Non-Hispanic Caucasian   PB       Prostate cancer   463    505       148   1116   554     602   188   1344   0.359   0.364   0.235     7
  Daugherty SE        2007   USA       African American         PB       Prostate cancer   73     23        2     98     277     98    5     380    0.138   0.142   0.261     7
  Nam RK              2005   Canada    Caucasian                PB       Prostate cancer   477    409       110   996    521     459   112   1092   0.316   0.313   0.464     7
  Wiklund F           2004   Sweden    Caucasian                PB       Prostate cancer   597    778       247   1622   297     384   115   796    0.392   0.386   0.611     6
  Nakazato H          2003   Japan     Asian                    HB       Prostate cancer   69     32        0     101    71      26    8     105    0.158   0.200   0.020     7
  Rokman A            2002   Finland   Caucasian                PB       Prostate cancer   60     83        24    167    69      84    23    176    0.392   0.369   0.745     6
  Fischer N           2008   Germany   Caucasian                HB       Prostate cancer   51     29        7     87     42      24    4     70     0.247   0.229   0.816     7
  Maier C             2005   Germany   Caucasian                HB       Prostate cancer   133    171       59    363    73      97    37    207    0.398   0.413   0.629     7
  Wang L              2002   USA       Caucasian                PB       Prostate cancer   389    427       102   918    193     233   67    493    0.344   0.372   0.802     7
  Cybulski C          2007   Poland    Caucasian                HB       Prostate cancer   245    376       116   737    177     252   82    511    0.412   0.407   0.625     6
  Kruger S            2005   Germany   Caucasian                HB       Prostate Cancer   91     126       34    251    163     212   64    439    0.386   0.387   0.713     6
  Shook SJ            2007   USA       Non-Hispanic Caucasian   PB       Prostate Cancer   187    183       60    430    221     225   57    503    0.352   0.337   0.981     7
  Shook SJ            2007   USA       Hispanic Caucasian       PB       Prostate Cancer   72     62        16    150    136     96    7     239    0.313   0.230   0.039     7
  Shook SJ            2007   USA       African American         PB       Prostate Cancer   45     13        10    68     111     31    3     145    0.243   0.128   0.633     7
  **rs627928 T\>G**                                                                                                                                                           
  Alvarez-Cubero MJ   2015   Spain     Caucasian                HB       Prostate Cancer   35     124       78    237    34      113   69    216    0.409   0.419   0.273     7
  San Francisco IF    2014   Chile     Hispanic Caucasian       HB       Prostate Cancer   34     31        18    83     7       9     5     21     0.596   0.548   0.536     6
  Meyer MS            2010   USA       Caucasian                PB       Prostate Cancer   277    560       378   1215   282     536   376   1194   0.458   0.461   \<0.001   7
  Beuten J            2010   USA       Hispanic Caucasian       PB       Prostate Cancer   41     45        70    156    59      48    120   227    0.407   0.366   \<0.001   6
  Robbins CM          2008   USA       African American         HB       Prostate Cancer   103    102       38    243    143     129   24    296    0.634   0.701   0.495     7
  Shea PR             2008   USA       Caucasian                PB       Prostate Cancer   107    97        26    230    217     201   40    458    0.676   0.693   0.496     6
  Noonan-Wheeler FC   2006   USA       Caucasian                HB       Prostate Cancer   22     73        55    150    33      93    44    170    0.390   0.468   0.198     7
  Wiklund F           2004   Sweden    Caucasian                PB       Prostate Cancer   273    768       522   1563   162     372   257   791    0.420   0.440   0.199     6
  Nakazato H          2003   Japan     Asian                    HB       Prostate Cancer   18     32        51    101    3       43    59    105    0.337   0.233   0.138     7
  Rokman A            2002   Finland   Caucasian                PB       Prostate Cancer   21     94        52    167    29      91    56    176    0.407   0.423   0.434     6
  Maier C             2005   Germany   Caucasian                HB       Prostate Cancer   62     176       125   363    41      97    69    207    0.413   0.432   0.514     7
  Cybulski C          2007   Poland    Caucasian                HB       Prostate Cancer   111    372       254   737    84      259   168   511    0.403   0.418   0.344     6
  Shook SJ            2007   USA       Non-Hispanic Caucasian   PB       Prostate Cancer   100    190       140   430    91      254   139   484    0.453   0.450   0.187     7
  Shook SJ            2007   USA       Hispanic Caucasian       PB       Prostate Cancer   41     66        43    150    69      125   48    242    0.493   0.543   0.525     7
  Shook SJ            2007   USA       African American         PB       Prostate Cancer   31     28        9     68     71      60    15    146    0.662   0.692   0.661     7

###### 

Meta-analysis of *RNASEL* gene polymorphism and the risk of prostate cancer.

  Variables                Genetic comparison   Number of studies   I^2^     P~Q~    95% CI              P~Z~    Model
  ------------------------ -------------------- ------------------- -------- ------- ------------------- ------- --------
  **rs486907**                                                                                                   
  All                      G *vs.* A            22                  0.00%    0.507   0.97 (0.94--1.01)   0.212   Fixed
                           GG+GA *vs*. AA       22                  10.80%   0.315   0.96 (0.88--1.04)   0.352   Fixed
                           GG *vs.* GA+AA       22                  0.00%    0.973   0.97 (0.92--1.03)   0.278   Fixed
                           GG *vs.* AA          22                  13.50%   0.280   0.95 (0.87--1.04)   0.301   Fixed
                           GA *vs.* GG          22                  0.00%    0.999   1.03 (0.97--1.09)   0.345   Fixed
  Ethnicity                                                                                                      
  African American         G *vs.* A            3                   69.50%   0.038   1.27 (0.80--2.01)   0.308   Random
                           GG+GA *vs.* AA       3                   56.90%   0.098   2.55 (0.74--8.72)   0.137   Random
                           GG *vs.* GA+AA       3                   9.90%    0.330   1.10 (0.83--1.45)   0.520   Fixed
                           GG *vs.* AA          3                   56.90%   0.098   2.53 (0.73--8.72)   0.141   Random
                           GA *vs.* GG          3                   0.00%    0.907   1.02 (0.76--1.37)   0.897   Fixed
  Caucasian                G *vs.* A            19                  0.00%    0.905   0.97 (0.93--1.01)   0.132   Fixed
                           GG+GA *vs.* AA       19                  0.00%    0.793   0.95 (0.87--1.03)   0.217   Fixed
                           GG *vs.* GA+AA       19                  0.00%    0.986   0.96 (0.91--1.02)   0.216   Fixed
                           GG *vs.* AA          19                  0.00%    0.748   0.94 (0.86--1.03)   0.175   Fixed
                           GA *vs.* GG          19                  0.00%    0.996   1.03 (0.97--1.09)   0.348   Fixed
  Non-Hispanic Caucasian   G *vs.* A            3                   0.00%    0.397   0.97 (0.89--1.05)   0.467   Fixed
                           GG+GA *vs.* AA       3                   57.30%   0.096   0.94 (0.72--1.21)   0.628   Random
                           GG *vs.* GA+AA       3                   0.00%    0.931   0.98 (0.88--1.10)   0.777   Fixed
                           GG *vs.* AA          3                   44.60%   0.164   0.92 (0.78--1.10)   0.354   Fixed
                           GA *vs.* GG          3                   0.00%    0.934   1.00 (0.89--1.12)   0.962   Fixed
  **rs627928**                                                                                                   
  All                      T *vs.* G            13                  18.90%   0.252   1.08 (1.01--1.15)   0.016   Fixed
                           TT+TG *vs.* GG       13                  13.40%   0.310   1.14 (1.03--1.25)   0.013   Fixed
                           TT *vs.* TG+GG       13                  38.00%   0.080   1.07 (0.92--1.25)   0.367   Random
                           TT *vs.* GG          13                  40.80%   0.062   1.21 (1.00--1.47)   0.054   Random
                           TG *vs.* TT          13                  42.10%   0.054   0.99 (0.84--1.17)   0.940   Random
  Ethnicity                                                                                                      
  Non-Caucasian            T *vs.* G            3                   80.30%   0.006   1.00 (0.62--1.61)   0.990   Random
                           TT+TG *vs.* GG       3                   67.20%   0.047   1.30 (0.68--2.48)   0.419   Random
                           TT *vs.* TG+GG       3                   82.70%   0.003   0.73 (0.30--1.75)   0.480   Random
                           TT *vs.* GG          3                   86.60%   0.001   0.84 (0.20--3.44)   0.805   Random
                           TG *vs.* TT          3                   80.40%   0.006   1.49 (0.63--3.57)   0.366   Random
  African American         T *vs.* G            2                   0.00%    0.516   1.30 (1.04--1.62)   0.020   Fixed
                           TT+TG *vs.* GG       2                   0.00%    0.388   1.86 (1.18--2.94)   0.008   Fixed
                           TT *vs.* TG+GG       2                   0.00%    0.732   1.23 (0.92--1.65)   0.164   Fixed
                           TT *vs.* GG          2                   0.00%    0.398   1.94 (1.20--3.14)   0.007   Fixed
                           TG *vs.* TT          2                   0.00%    0.942   0.92 (0.67--1.25)   0.588   Fixed
  Caucasian                T *vs.* G            10                  0.00%    0.868   1.08 (1.01--1.15)   0.028   Fixed
                           TT+TG *vs.* GG       10                  0.00%    0.626   1.12 (1.01--1.24)   0.032   Fixed
                           TT *vs.* TG+GG       10                  0.00%    0.539   1.09 (0.97--1.22)   0.169   Fixed
                           TT *vs.* GG          10                  0.00%    0.815   1.18 (1.03--1.36)   0.018   Fixed
                           TG *vs.* TT          10                  13.80%   0.316   0.96 (0.85--1.09)   0.515   Fixed

###### 

Publication bias analysis of the meta-analysis.

  Variables      Genetic comparison   Begg's test P value   Egger's test           
  -------------- -------------------- --------------------- -------------- ------- -------------
  **rs486907**                                                                     
  All            G *vs.* A            0.693                 0.28           0.783   −0.84, 1.10
                 GG+GA *vs.* AA       0.652                 0.75           0.464   −0.61, 1.29
                 GG *vs.* GA+AA       0.910                 0.11           0.910   −0.67, 0.75
                 GG *vs.* AA          0.652                 0.66           0.515   −0.66, 1.27
                 GA *vs.* GG          0.735                 0.18           0.863   −0.50, 0.59
  Caucasian      G *vs.* A            0.234                 −1.16          0.260   −1.33, 0.38
                 GG+GA *vs.* AA       0.441                 −0.75          0.466   −1.26, 0.60
                 GG *vs.* GA+AA       0.484                 −0.77          0.453   −0.98, 0.46
                 GG *vs.* AA          0.576                 −0.78          0.445   −1.30, 0.59
                 GA *vs.* GG          0.726                 0.22           0.830   −0.59, 0.72
  **rs627928**                                                                     
  All            T *vs.* G            0.855                 −0.41          0.691   −2.11, 1.45
                 TT+TG *vs.* GG       0.300                 1.21           0.252   −0.67, 2.29
                 TT *vs.* TG+GG       0.360                 −1.46          0.173   −3.10, 0.63
                 TT *vs.* GG          0.951                 −0.48          0.642   −2.36, 1.52
                 TG *vs.* TT          0.360                 1.56           0.147   −0.56, 3.27
  Caucasian      T *vs.* G            1.000                 0.28           0.789   −1.28, 1.63
                 TT+TG *vs.* GG       0.210                 1.20           0.266   −0.74, 2.34
                 TT *vs.* TG+GG       0.858                 −0.19          0.857   −2.11, 1.79
                 TT *vs.* GG          0.721                 0.49           0.636   −1.17, 1.81
                 TG *vs.* TT          0.721                 0.39           0.705   −1.85, 2.60
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